Core Viewpoint - Watson Bio expects to achieve revenue of 2.4 billion to 2.43 billion yuan and a net profit attributable to shareholders of 160 million to 190 million yuan in 2025, reflecting a year-on-year growth of 13% to 34% [2] Group 1: Financial Performance - The company anticipates a narrowing decline in domestic vaccine product revenue and continuous growth in international vaccine product revenue, with export vaccine revenue increasing by approximately 35% compared to the previous year [2] - Operational management capabilities have improved due to ongoing cost reduction and efficiency enhancement measures, contributing to the growth in net profit [2] Group 2: International Expansion - By the end of 2025, Watson Bio's vaccine products have been exported to 24 countries and regions, with a successful entry into the Latin American market for its core product, the 23-valent pneumonia vaccine [2] - The company is advancing over 30 international product registration projects covering around 20 countries, including core products like pneumonia and HPV vaccines, laying a solid foundation for sustained overseas revenue growth [2] Group 3: Innovation and R&D - Watson Bio maintains a high level of investment in innovative vaccine research and development, collaborating with renowned universities and research institutions to integrate resources and accelerate the development of multiple innovative vaccines [4] - The company has established an mRNA vaccine technology platform in collaboration with Fudan University and Shanghai Bluebird Biopharmaceuticals, with several mRNA vaccines receiving clinical trial approval [3][4] - The competitive nature of the vaccine industry necessitates continuous strengthening of core technological barriers and operational optimization through an "innovation + management" dual-drive model [4]

Group 1: Major Developments - 康耐特光学 (02276) and 歌尔光学 plan to establish a joint venture to expand the application market for customized lenses in AI/AR/VR/MR glasses [1] - 圣贝拉 (02508) and 云迹科技 signed a strategic cooperation framework agreement to explore the deep integration and application of artificial intelligence and robotics in high-demand home care scenarios [1] - KKCG Maritime intends to initiate a voluntary conditional partial public acquisition offer to acquire 15.4% of 法拉帝 (09638) shares [1] - 远大医药 (00512) announced that the new drug application for the innovative radiolabeled drug TLX591-CDx has been accepted by the China National Medical Products Administration [1] - 艾美疫苗 (06660) received approval to conduct clinical trials for a 20-valent pneumococcal polysaccharide conjugate vaccine [1] - 中国东方航空股份 (00670) sold the 凯迪克大厦 in Shanghai and related assets to 东航置业 for approximately 134 million yuan [1] - 佑驾创新 (02431) signed a memorandum of understanding with India's leading automotive parts manufacturer STL [1] - 南山铝业国际 (02610) plans to develop electrolytic aluminum and related raw materials and supporting businesses [1] Group 2: Financial Performance - 顺丰控股 (06936) reported a total revenue of 27.339 billion yuan from its express logistics, supply chain, and international businesses in December, representing a year-on-year increase of 3.41% [2] - 美丽田园医疗健康 (02373) issued a profit warning, expecting adjusted net profit for 2025 to be no less than 380 million yuan, a year-on-year increase of at least 40% [2] - 中国太平 (00966) issued a profit warning, anticipating a year-on-year increase of approximately 215% to 225% in shareholder profit for the 2025 fiscal year [2] - 吉宏股份 (02603) issued a profit warning, expecting a net profit attributable to shareholders of approximately 273 million to 291 million yuan for 2025, a year-on-year increase of 50% to 60% [2] - 兖煤澳大利亚 (03668) reported a fourth-quarter coal sales volume of 10.8 million tons, a year-on-year increase of 4% [2] - 兖矿能源 (01171) reported a fourth-quarter commodity coal production of 46.51 million tons, a year-on-year increase of 4.4% [2] - 深圳控股 (00604) projected a total contract sales amount of approximately 13.311 billion yuan for 2025, a year-on-year decrease of 21.55% [2] - 上海石油化工股份 (00338) issued a profit warning, expecting a net loss attributable to shareholders of approximately 1.289 billion to 1.576 billion yuan for 2025, indicating a shift from profit to loss [2] - 上海石油化工股份 (00338) reported gasoline sales revenue of 24.656 billion yuan for 2025 [2]

Core Viewpoint - The company has developed an upgraded 20-valent pneumococcal conjugate vaccine based on the existing 13-valent vaccine, which has received approval for clinical trials from the National Medical Products Administration [1][4]. Group 1: Vaccine Development - The new 20-valent pneumococcal conjugate vaccine includes 7 additional serotypes, covering a total of 20 serotypes that are currently prevalent, aimed at preventing invasive diseases such as pneumonia, meningitis, and bacteremia [3]. - The vaccine is intended for administration to individuals aged 2 months and older, targeting infections caused by the 20 serotypes included in the vaccine [3]. Group 2: Public Health Significance - Pneumococcal diseases are a significant global public health issue, being a major cause of morbidity and mortality among children and adults in China [2]. - The World Health Organization (WHO) classifies pneumococcal diseases as requiring "extremely high priority" for vaccine prevention, highlighting the urgent need for effective vaccination strategies [2]. Group 3: Market Position and Future Plans - The approval of the 20-valent vaccine for clinical trials enhances the company's pipeline in the pneumococcal vaccine sector, indicating a commitment to addressing unmet clinical needs in core disease areas [4]. - The company aims to continue advancing innovative vaccine development to improve its innovation capabilities, core competitiveness, and overall strength in the market [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 – 1 – 全 部 位 於 非 洲 和 亞 洲，佔 全 球 總 病 例 數 的66%，而 中 國 位 列 第 二，佔 全 球 總病例數的12%。WHO對 可 用 疫 苗 預 防 的 疾 病 的 分 級 中，將 肺 炎 球 菌 性 疾 病 定 為 需「極 高 度 優 先」使 用 疫 苗 預 防 的 疾 病。 AIM Vaccine Co., Ltd. 艾美疫苗股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：06660） 自願性公告 20價肺炎球菌多糖結合疫苗 獲批開展臨床試驗 本 公 告 由 艾 美 疫 苗 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）自 願 作 出，以 告 知 本 公 司 股 東 及 潛 在 投 資 者 本 集 團 ...

Core Insights - The company reported a revenue of 2.063 billion yuan for the first three quarters of 2025, a year-on-year increase of 2.24%, while the net profit attributable to shareholders was 49.1577 million yuan, a significant decline of 86.0% due to changes in product sales structure and corresponding cost increases [1] - The company is actively pursuing an internationalization strategy, achieving overseas revenue of 41.9 million yuan, a remarkable growth of 324.27% year-on-year, with multiple product approvals in various countries [2] - The company maintains a high level of R&D investment, with R&D expenses reaching 420 million yuan, a year-on-year increase of 34.74%, indicating a strong pipeline of multi-valent vaccines in advanced clinical stages [3] - The company is expected to see net profits of 122 million yuan, 421 million yuan, and 510 million yuan from 2025 to 2027, with corresponding price-to-earnings ratios of 151, 44, and 36 times, maintaining a "recommended" rating [4] Financial Performance - For the first three quarters of 2025, the company's main revenue was 2.063 billion yuan, with a net profit of 49.1577 million yuan, reflecting an 86.0% decline [1] - The net cash flow from operating activities was 362 million yuan, a year-on-year increase of 53.45%, attributed to increased sales collections [1] - In Q3 2025, the company reported a single-quarter revenue of 671 million yuan, a year-on-year decrease of 17.74%, and a net profit of 11.6249 million yuan, down 93.74% [1] International Expansion - The company has made significant strides in international markets, with overseas revenue reaching 41.9 million yuan, a growth of 324.27% year-on-year [2] - Key product approvals include the 13-valent pneumococcal polysaccharide conjugate vaccine in Turkey, Indonesia, Nicaragua, and Pakistan, marking successful entries into various international markets [2] - The company's international footprint now spans over 20 countries, with ongoing collaborations in densely populated regions under initiatives like the "Belt and Road" [2] Research and Development - R&D expenses for the first three quarters of 2025 were 420 million yuan, representing a 34.74% increase, with an R&D expense ratio of 20.36% [3] - Several products are in critical clinical stages, including the Sabin strain inactivated polio vaccine and the oral pentavalent reconstituted rotavirus vaccine, among others [3] - The company is also proactively developing innovative vaccines targeting challenging pathogens, such as Klebsiella pneumoniae, which is known for its antibiotic resistance [3]

Group 1 - The company has launched two pneumococcal vaccines: a 13-valent pneumococcal polysaccharide conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine [2] - The company is currently conducting clinical research on a 20-valent pneumococcal polysaccharide conjugate vaccine, which received the Drug Clinical Trial Approval Notification in April 2025 and is preparing for Phase I clinical research [2]

Core Viewpoint - Watson Bio has a total of 8 self-developed vaccine products (14 specifications) officially on the market, aimed at preventing diseases caused by specific pathogenic microorganisms [1] Product Overview - The company’s vaccine products include: - 13-valent pneumococcal conjugate vaccine (vial type and pre-filled type) - Bivalent HPV vaccine (vial type and pre-filled type) - 23-valent pneumococcal polysaccharide vaccine (vial type and pre-filled type) - Haemophilus influenzae type b conjugate vaccine (vial type and pre-filled type) - Group A and C meningococcal polysaccharide conjugate vaccine (vial type and pre-filled type) - ACYW135 group meningococcal polysaccharide vaccine (vial type and pre-filled type) - Group A and C meningococcal polysaccharide vaccine (vial type) - Adsorbed acellular DTP combined vaccine (vial type) [1] Research and Development - The company’s 20-valent pneumococcal polysaccharide conjugate vaccine received the "Drug Clinical Trial Approval Notice" in April 2025 and is currently preparing for Phase I clinical research [1] - The company will disclose any substantial and phase-related progress in the research and development of its vaccine products in a timely manner [1]

Core Viewpoint - The company has a total of 8 self-developed vaccine products officially on the market, with various specifications, and is actively engaged in the development of new vaccines [2]. Group 1: Current Vaccine Products - The company has 8 self-developed vaccine products (14 specifications) officially available for sale, including: - 13-valent pneumococcal conjugate vaccine (vial and pre-filled syringe types) - Bivalent HPV vaccine (vial and pre-filled syringe types) - 23-valent pneumococcal polysaccharide vaccine (vial and pre-filled syringe types) - Haemophilus influenzae type b conjugate vaccine (vial and pre-filled syringe types) - Meningococcal polysaccharide conjugate vaccines for groups A and C (vial and pre-filled syringe types) - Meningococcal polysaccharide vaccine for groups ACYW135 (vial and pre-filled syringe types) - Meningococcal polysaccharide vaccine for groups A and C (vial type) - Adsorbed acellular DTP combined vaccine (vial type) [2]. Group 2: Future Developments - The company’s 20-valent pneumococcal polysaccharide conjugate vaccine is expected to receive the "Drug Clinical Trial Approval Notification" in April 2025 and is currently preparing for Phase I clinical research [2]. - The company will disclose any substantial and phase-related progress in the development of its vaccine products in a timely manner [2].

Core Viewpoint - Shenzhen Kangtai Biological Products Co., Ltd. reported a revenue of 1.392 billion yuan for the first half of 2025, marking a year-on-year increase of 15.81% [2] Financial Performance - The company achieved a net cash flow from operating activities of 75.597 million yuan, up 31.42% year-on-year [2] - Research and development expenditure reached 334 million yuan, representing a 41.52% increase and accounting for 23.96% of total revenue [2] - The company maintained a stable financial position with a cumulative net cash flow of approximately 2.2 billion yuan over the past three years (2022-2024) [3] Research and Development - Kangtai is accelerating its transformation into a global innovative biopharmaceutical company, focusing on public health challenges and innovative vaccine development [2] - The company is developing a vaccine targeting Klebsiella pneumoniae, which is listed as a critical priority pathogen by the World Health Organization [2] - The company has nearly 30 ongoing research projects, with 3 in the production registration application stage and 15 in clinical trials [3] Strategic Partnerships - A joint venture with AstraZeneca was established to develop a combination vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), which currently has no similar products on the global market [3] - The company has agreements with over 20 countries, including Indonesia, Pakistan, and Bangladesh, for the registration and promotion of its pneumococcal polysaccharide vaccines [4] Future Outlook - Kangtai aims to enhance its product commercialization capabilities and accelerate its transition into a global innovative biopharmaceutical enterprise through overseas cooperation and technology transfer [4]

Core Viewpoint - 康泰生物 reported a significant increase in revenue and R&D investment, indicating strong growth potential in the vaccine sector and ongoing innovation in vaccine development [1][2] Group 1: Financial Performance - In the first half of 2025, the company achieved operating revenue of 1.392 billion yuan, a year-on-year increase of 15.81% [1] - In Q2, the company generated operating revenue of 747 million yuan, reflecting a quarter-on-quarter growth of 15.76% [1] - R&D investment reached 334 million yuan, up 41.52% year-on-year, accounting for 23.96% of the operating revenue [1] Group 2: Vaccine Development Initiatives - The company is focusing on global innovative vaccine products, particularly developing a vaccine for Klebsiella pneumoniae, which is known for its antibiotic resistance and pathogenicity [1] - 康泰生物 established a joint venture with AstraZeneca to develop innovative vaccines for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), with no similar products currently available globally [1] - The company has nearly 30 projects under development, with 3 in the production registration application stage and 15 in clinical trial stages [2] Group 3: Progress on Research Projects - The 60μg recombinant hepatitis B vaccine aimed at preventing recurrence in functional cure populations has received Pre-IND feedback from CDE and is in the process of completing clinical application documentation [2] - The five-in-one vaccine (DTPaHibIPV) has obtained preliminary data from Phase I clinical trials and is currently in discussions with CDE regarding Phase III clinical matters [2] - The 20-valent pneumococcal polysaccharide conjugate vaccine is in Phase I and II clinical trials, while the 24-valent pneumococcal polysaccharide conjugate vaccine has completed preclinical research and received Pre-IND feedback from CDE [2]